Broad immune inflammatory signaling

Broad immune inflammatory signaling refers to the integrated network of biochemical pathways that mediate the body's inflammatory response to stimuli such as pathogens or tissue damage (Source: StatPearls, 2023). Rather than a single molecular target, it encompasses various signaling cascades including the NF-κB, JAK/STAT, and MAPK pathways, which are triggered by a wide array of cytokines, chemokines, and pattern recognition receptors (Source: Nature Reviews Immunology, 2017). Dysregulation of these broad signaling networks is a hallmark of chronic inflammatory and autoimmune diseases, where persistent activation leads to tissue destruction and systemic pathology (Source: NIH, 2022). Pharmacological intervention typically involves broad-spectrum agents like corticosteroids or more specific inhibitors that target key nodes within these pathways to dampen the overall inflammatory output (Source: PubChem). Because these pathways are essential for host defense, therapeutic modulation carries significant risks, most notably systemic immunosuppression and an increased susceptibility to infections (Source: FDA).

Other names

Inflammatory signaling pathwaysImmune-mediated inflammatory responseSystemic inflammatory signaling cascadesPro-inflammatory signaling network

The mechanism of action involves the systemic or multi-pathway inhibition of pro-inflammatory mediators, such as cytokines and chemokines, and the suppression of intracellular signaling molecules like Janus kinases (JAKs) or transcription factors like NF-κB (Source: PubMed, 2021).